Dr. Shah has served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics Inc., Inpharmakon, Inc., Protomed Inc., Structural Bioinformatics Inc., and Zarix Inc. He received his Ph.D. in industrial pharmacy from St. John's University and his Bachelors and Masters Degree in Pharmacy from L.M. College of Pharmacy in Gujarat, India.
DCCR is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation, currently in development for patients with very high triglycerides. Essentialis expects to initiate Phase III clinical trials in 2012. DCCR is covered by multiple issued US patents, which provide composition of matter protection until 2028. Essentialis has evaluated DCCR in double-blind, placebo-controlled studies that demonstrated the drug was well tolerated, and achieved various statistically significant endpoints in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide during the last 40 years, and more than 3,000 peer reviewed publications covering in-vitro, animal model and clinical results with diazoxide, support the acceptable safety of DCCR.
About Essentialis, Inc.
Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide
|SOURCE Essentialis, Inc.|
Copyright©2010 PR Newswire.
All rights reserved